公开(公告)号：US20240360453A1

公开(公告)日：2024-10-31

申请号：US18523746

申请日：2023-11-29

申请人： Ionis Pharmaceuticals, Inc.

发明人： Tracy A. Cole ,  Holly Kordasiewicz ,  Huynh-Hoa Bui ,  Susan M. Freier

IPC分类号： C12N15/113 ,  A61K31/7125 ,  A61K47/02 ,  A61K47/46 ,  A61P25/16

CPC分类号： C12N15/1137 ,  A61K31/7125 ,  A61K47/02 ,  A61K47/46 ,  A61P25/16 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of LRRK2 RNA in a cell or animal, and in certain instances reducing the amount of LRRK2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include Parkinson's disease.

公开(公告)号：US20240358729A1

公开(公告)日：2024-10-31

申请号：US18566456

申请日：2023-04-26

申请人： ADVANCED PROTEIN TECHNOLOGIES CORP.

发明人： Seong Jin YU ,  Kuo Jen WU ,  Yun WANG ,  Chul Soo SHIN ,  Jong Won YOON ,  Seon Min JEON ,  Young Ha SONG ,  Jong Gil YOO ,  Ji Eun KIM

IPC分类号： A61K31/702 ,  A61P25/16

CPC分类号： A61K31/702 ,  A61P25/16

摘要： Disclosed is a composition containing 2′-FL for ameliorating, preventing or treating diseases caused by reduction of dopamine. 2′-FL has an advantage of effectively preventing or treating diseases caused by a decrease in dopamine by effectively suppressing degeneration of dopaminergic neurons. In particular, the composition of the present invention is effective in preventing, treating, or ameliorating Parkinson's disease caused by reduction of dopamine because it contains 2′-fucosyllactose (2′-FL) as an active ingredient, thereby suppressing the decrease in dopaminergic neurons and exhibiting an effect of improving motor activity.

公开(公告)号：US20240352031A1

公开(公告)日：2024-10-24

申请号：US18673818

申请日：2024-05-24

申请人： Emory University

发明人： Stephen F. Traynelis ,  Lanny S. Liebeskind ,  Dennis C. Liotta ,  Ethel C. Garnier-Amblard ,  PavanKumar Reddy Gangireddy

IPC分类号： C07D495/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28

CPC分类号： C07D495/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/28

摘要： The disclosure relates thieno[2,3-d]pyrimidin-4-one derivatives as modulators of NMDA receptors and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing conditions related to cognition, typically prevention or treatment of neurological conditions related to the NMDA receptor.

公开(公告)号：US20240342124A1

公开(公告)日：2024-10-17

申请号：US18636148

申请日：2024-04-15

申请人： NeuroDerm, Ltd.

发明人： Liat Adar ,  Nelson Felix Lopes ,  Laurence Salin ,  Tamar Yardeni ,  Nissim Sasson ,  Sheila Oren ,  Hikari Yarita ,  Mikio Himizu ,  Natalia Vostokova

IPC分类号： A61K31/195 ,  A61K9/00 ,  A61K31/198 ,  A61P25/16 ,  A61P25/20

CPC分类号： A61K31/195 ,  A61K9/0019 ,  A61K31/198 ,  A61P25/16 ,  A61P25/20

摘要： Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in a patient in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof.

公开(公告)号：US20240336577A1

公开(公告)日：2024-10-10

申请号：US18018884

申请日：2021-07-30

申请人： SHENZHEN OLIVE BIOPHARMACEUTICALS CO., LTD

发明人： Xifei YANG ,  Yongmei XIE ,  Shupeng LI

IPC分类号： C07D241/12 ,  A61K31/4965 ,  A61P25/16 ,  A61P25/28

CPC分类号： C07D241/12 ,  A61K31/4965 ,  A61P25/16 ,  A61P25/28

摘要： The present disclosure relates to use of a pyrazine compound in preparation of a drug. The drug can treat a neurodegenerative disease (ND) including Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal dementia (FTD), vascular dementia, HIV-related dementia, multiple sclerosis, progressive lateral sclerosis, Friedreich's ataxia, neuropathic pain, or glaucoma. The drug can further treat an inflammation, an oxidative damage, and a mitochondrial disorder-related disease.

公开(公告)号：US20240316002A1

公开(公告)日：2024-09-26

申请号：US18679418

申请日：2024-05-30

申请人： GBS Global BioPharma, Inc.

发明人： Andrea Lee Small-Howard

IPC分类号： A61K31/352 ,  A61K31/05 ,  A61P25/16

CPC分类号： A61K31/352 ,  A61K31/05 ,  A61P25/16

摘要： Provided herein are cannabinoid-ratio defined formulations suitable for use as an active pharmaceutical ingredient. Also provided are methods of making the cannabinoid-ratio defined formulations; pharmaceutical compositions comprising the cannabinoid-ratio defined formulations, and methods of using the pharmaceutical compositions for the treatment of Parkinsonian movement disorders, including Parkinson's disease, parkinsonism, and dopamine-related Parkinson's disease symptoms.

公开(公告)号：US12098173B2

公开(公告)日：2024-09-24

申请号：US17057418

申请日：2019-05-22

申请人： The Governors of the University of Alberta

发明人： Holger Wille ,  Jiarui Fang ,  José Miguel Flores-Fernández ,  Vineet Rathod ,  Xinli Tang

IPC分类号： C07K14/47 ,  A61K39/00 ,  A61K39/385 ,  A61P25/16 ,  A61P25/28 ,  A61P37/04 ,  C07K14/195 ,  C07K14/285 ,  C07K14/37 ,  C07K14/705 ,  C07K16/12 ,  C07K16/14 ,  C07K16/18 ,  C07K16/28 ,  C12N9/88

CPC分类号： C07K14/47 ,  A61K39/0007 ,  A61K39/385 ,  A61P25/16 ,  A61P25/28 ,  A61P37/04 ,  C07K14/195 ,  C07K14/285 ,  C07K14/37 ,  C07K14/70596 ,  C07K16/1203 ,  C07K16/1242 ,  C07K16/14 ,  C07K16/18 ,  C07K16/2872 ,  C12N9/88 ,  C12Y402/02002 ,  A61K2039/6031 ,  A61K2039/6068 ,  C07K2319/33

摘要： The present disclosure relates generally to polypeptides, which may be used of the treatment of neurological diseases or disorders.

公开(公告)号：US20240269318A1

公开(公告)日：2024-08-15

申请号：US18626620

申请日：2024-04-04

申请人： TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED

发明人： Avi SCHROEDER ,  Mor SELA

IPC分类号： A61K47/69 ,  A61P25/16 ,  B82Y5/00

CPC分类号： A61K47/6911 ,  A61P25/16 ,  B82Y5/00

摘要： In one aspect of the invention, there is provided a nanoparticle comprising a core and a shell, wherein the core comprises a bioactive compound, and the shell comprises a lipid layer comprising a first modified lipid and a additional lipid, wherein the first modified lipid is bound to a targeted moiety via a spacer, and wherein the additional lipid comprises a polymer-bound lipid. The present invention further provides pharmaceutical compositions and methods for therapeutic and/or diagnostic use.

公开(公告)号：US20240269104A1

公开(公告)日：2024-08-15

申请号：US18444049

申请日：2024-02-16

申请人： Olatec Therapeutics, Inc.

发明人： Charles A. Dinarello ,  Jesus Amo Aparicio

IPC分类号： A61K31/275 ,  A61P25/16

CPC分类号： A61K31/275 ,  A61P25/16

摘要： The present invention is directed to a method for treating Parkinson's disease. The method comprises administering to a subject in need thereof dapansutrile, in an effective amount. Dapansutrile minimizes the clinical features of PD such as locomotor impairments through the modulation of the inflammatory response, reduction in α-synuclein levels, and protection of dopaminergic neurons. A preferred route of administration is oral administration.

公开(公告)号：US20240252680A1

公开(公告)日：2024-08-01

申请号：US18290124

申请日：2022-04-21

申请人： INNOPEUTICS CORPORATION

发明人： Sang Hun LEE ,  Yun Seon YANG ,  Min Jong SEOK ,  Tae Gyun KIM ,  Seonghoon LEE

IPC分类号： A61K48/00 ,  A61K35/30 ,  A61K38/17 ,  A61P25/16 ,  C12N15/86

CPC分类号： A61K48/005 ,  A61K35/30 ,  A61K38/1709 ,  A61P25/16 ,  C12N15/86 ,  C12N2750/14143

摘要： The present invention relates to a composition for inhibiting alpha-synuclein aggregation and a method for inhibiting alpha-synuclein aggregation and, more specifically, to techniques for inhibiting alpha-synuclein aggregation and phosphorylation by introducing Nurr1 and Foxa2 genes to induce the expressions thereof, and the composition according to the present disclosure has an excellent effect of inhibiting α-synuclein aggregation and phosphorylation and thus can be used in the treatment and prevention of Parkinson's disease.